Guggenheim raises target for Elevance Health stock to USD 460
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Guggenheim has increased its price target for Elevance Health (ELV) stock to USD 460, maintaining a "Buy" rating. This adjustment reflects improved performance across the company's Medicaid, Medicare Advantage, and ACA businesses, as well as higher 2027 earnings estimates. Investors are awaiting Elevance Health's third-quarter 2026 results on October 21, 2026, which will further clarify the company's financial trajectory.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.